Karyopharm Therapeutics Inc. , a clinical-stage pharmaceutical company, today announced that fourteen abstracts describing the activity of selinexor , the company's lead drug candidate in development for hematological malignancies and solid tumors, have been selected for presentation at the 2015 Annual Meeting of the American Association for Cancer Research taking place April 18-22 in Philadelphia. The abstracts, which represent both company and investigator-sponsored preclinical studies, describe data related to selinexor , Karyopharm's first-in-class, oral Selective Inhibitor of Nuclear Export / SINE compound that inhibits exportin 1 .
http://ift.tt/1CwRsGT
http://ift.tt/1CwRsGT
No comments:
Post a Comment